Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer
Abstract Background Tyrosine kinase inhibitors (TKIs) are a class of molecular targeted drugs designed to selectively inhibit tyrosine kinase activity associated with oncogenic signaling pathways and drivers, and have emerged as key therapeutic agents for colorectal cancer (CRC). The purpose of this...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14639-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849764771536044032 |
|---|---|
| author | Xiaosong Li Zhenlong Chen Jie Yin Xiping Shen Hang Li |
| author_facet | Xiaosong Li Zhenlong Chen Jie Yin Xiping Shen Hang Li |
| author_sort | Xiaosong Li |
| collection | DOAJ |
| description | Abstract Background Tyrosine kinase inhibitors (TKIs) are a class of molecular targeted drugs designed to selectively inhibit tyrosine kinase activity associated with oncogenic signaling pathways and drivers, and have emerged as key therapeutic agents for colorectal cancer (CRC). The purpose of this study is to explore the research status and development trend of TKIs in CRC treatment. Methods The Web of Science Core Collection (WoSCC) database was systematically searched for publications related to TKIs for the treatment of CRC from 2015 to 2024. The CiteSpace visualization software were employed to visualization analysis. Results A total of 1151 papers published between 2015 and 2024 were included in this study. The USA was the most productive and influential country in this field. The University of Texas System and University of California System were identified as the most productive and most cited institutions, respectively. Cancers has the highest publication volume in this field. Trusolino Livio and Van Cutsem Eric were identified as the most prolific and most frequently co-cited authors, respectively. The article titled “Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways” published in Cancers in 2017, received the highest citation frequency. The emerging keywords that persisted into 2024 include “microsatellite instability”, “biological evaluation”, “drug discovery”, “inhibitors”, “regorafenib”, “immunotherapy”, and “T-cells”. Conclusion Current research hotspots include development of novel TKIs, elucidation of TKIs resistance mechanisms and corresponding overcoming strategies, evaluation of TKIs efficacy and safety through biological assessments, and combination of TKIs with immunotherapy. Precision medicine, multimodal combination therapies, and interdisciplinary integration represent the frontier research areas and future development directions. |
| format | Article |
| id | doaj-art-ece431a1d2d24933ac39f7a2096f9a88 |
| institution | DOAJ |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-ece431a1d2d24933ac39f7a2096f9a882025-08-20T03:05:03ZengBMCBMC Cancer1471-24072025-07-012511910.1186/s12885-025-14639-2Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancerXiaosong Li0Zhenlong Chen1Jie Yin2Xiping Shen3Hang Li4Department of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow UniversityDepartment of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow UniversityDepartment of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow UniversityDepartment of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow UniversityDepartment of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow UniversityAbstract Background Tyrosine kinase inhibitors (TKIs) are a class of molecular targeted drugs designed to selectively inhibit tyrosine kinase activity associated with oncogenic signaling pathways and drivers, and have emerged as key therapeutic agents for colorectal cancer (CRC). The purpose of this study is to explore the research status and development trend of TKIs in CRC treatment. Methods The Web of Science Core Collection (WoSCC) database was systematically searched for publications related to TKIs for the treatment of CRC from 2015 to 2024. The CiteSpace visualization software were employed to visualization analysis. Results A total of 1151 papers published between 2015 and 2024 were included in this study. The USA was the most productive and influential country in this field. The University of Texas System and University of California System were identified as the most productive and most cited institutions, respectively. Cancers has the highest publication volume in this field. Trusolino Livio and Van Cutsem Eric were identified as the most prolific and most frequently co-cited authors, respectively. The article titled “Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways” published in Cancers in 2017, received the highest citation frequency. The emerging keywords that persisted into 2024 include “microsatellite instability”, “biological evaluation”, “drug discovery”, “inhibitors”, “regorafenib”, “immunotherapy”, and “T-cells”. Conclusion Current research hotspots include development of novel TKIs, elucidation of TKIs resistance mechanisms and corresponding overcoming strategies, evaluation of TKIs efficacy and safety through biological assessments, and combination of TKIs with immunotherapy. Precision medicine, multimodal combination therapies, and interdisciplinary integration represent the frontier research areas and future development directions.https://doi.org/10.1186/s12885-025-14639-2Colorectal cancerTyrosine kinase inhibitorsTargeted therapyImmunotherapyTumor microenvironment |
| spellingShingle | Xiaosong Li Zhenlong Chen Jie Yin Xiping Shen Hang Li Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer BMC Cancer Colorectal cancer Tyrosine kinase inhibitors Targeted therapy Immunotherapy Tumor microenvironment |
| title | Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer |
| title_full | Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer |
| title_fullStr | Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer |
| title_full_unstemmed | Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer |
| title_short | Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer |
| title_sort | exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer |
| topic | Colorectal cancer Tyrosine kinase inhibitors Targeted therapy Immunotherapy Tumor microenvironment |
| url | https://doi.org/10.1186/s12885-025-14639-2 |
| work_keys_str_mv | AT xiaosongli exploringresearchfrontiersandemergingtrendsoftyrosinekinaseinhibitorsinthetreatmentofcolorectalcancer AT zhenlongchen exploringresearchfrontiersandemergingtrendsoftyrosinekinaseinhibitorsinthetreatmentofcolorectalcancer AT jieyin exploringresearchfrontiersandemergingtrendsoftyrosinekinaseinhibitorsinthetreatmentofcolorectalcancer AT xipingshen exploringresearchfrontiersandemergingtrendsoftyrosinekinaseinhibitorsinthetreatmentofcolorectalcancer AT hangli exploringresearchfrontiersandemergingtrendsoftyrosinekinaseinhibitorsinthetreatmentofcolorectalcancer |